Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases

BMJ – among women aged 40-79 with a primary diagnosis of VTE, oral therapy was associated with a significantly increased risk of VTE while transdermal preparations were not associated with an increased risk of VTE. Transdermal treatment appears to be underused, with the overwhelming preference still for oral preparations. Read More →

Read More
Brea Neri
IDSA releases updated clinical practice guidelines for the diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza

IDSA released updated clinical practice guidelines for the diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. The guidelines consider the care of children and adults, including special populations such as pregnant and postpartum women and immunocompromised patients. Read More →

Read More
Brea Neri
Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ (albuterol sulfate 117 mcg) Inhalation Powder

Teva - announced that the FDA has approved ProAir® Digihaler™ (albuterol sulfate 117 mcg) inhalation powder, the first and only digital inhaler with built-in sensors which connects to a companion mobile application and provides inhaler use information to people with asthma and COPD. ProAir® Digihaler™ will be available in 2019 through a small number of “Early Experience” Programs. Read More →

Read More
Brea Neri
AHA: Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association

AHA recently released a scientific statement reiterating that in patients for whom statin treatment is recommended by current guidelines, the benefits greatly outweigh the risks. In the US, roughly 10% of patients stop taking a statin because of subjective complaints, most commonly muscle symptoms without raised creatine kinase. In contrast, in RCTs, the difference in the incidence of muscle symptoms without significantly raised creatinine kinase in statin-treated compared with placebo-treated participants is <1% which suggests that muscle symptoms are usually not caused by the statin. Read More →

Read More
Brea Neri
JAMA: Opioids for Chronic Noncancer Pain A Systematic Review and Meta-analysis

JAMA - In this meta-analysis that included 96 randomized clinical trials and 26,169 patients with chronic noncancer pain, the use of opioids compared with placebo was associated with significantly less pain (−0.69 cm on a 10-cm scale) and significantly improved physical functioning (2.04 of 100 points), but the magnitude of the association was small. Opioid use was significantly associated with increased risk of vomiting. Comparisons of opioids with nonopioid alternatives suggested that the benefit for pain and functioning may be similar. Read More →

Read More
Brea Neri
ADA releases annual update to the Standards of Medical Care in Diabetes for 2019

ADA released their annual update to the Standards of Medical Care in Diabetes for 2019. It is intended to provide clinicians, patients, researchers, payers, and other interested inviduals with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care. To improve access, the Standards of Care is now available through ADA’s new interactive app, along with tools and calculators that can help guide patient care. Read More →

Read More
Brea Neri
JAMA: Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding

Among patients initiating oral anticoagulant treatment, incidence of hospitalization for upper gastrointestinal tract bleeding was the highest in patients prescribed rivaroxaban, and the lowest for patients prescribed apixaban. For each anticoagulant, the incidence of hospitalization for upper gastrointestinal tract bleeding was lower among patients who were receiving PPI cotherapy. Read More →

Read More
Brea Neri
FDA approves Shire’s Motegrity™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC)

Shire announced that the FDA has approved Motegrity (prucalopride), a once-daily, oral treatment option for adults with Chronic Idiopathic Constipation (CIC). Motegrity, a selective serotonin-4 (5-HT4) receptor agonist, provides a different class of treatment for CIC that works by enhancing colonic peristalsis to increase bowel motility. Motegrity is expected to launch in 2019 in the United States. Read More →

Read More
Brea Neri
FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients

FDA released warning about an increased risk of ruptures or tears in the aorta with fluoroquinolone antibiotics in certain patients. The FDA states that fluoroquinolones should not be used in patients at increased risk unless there are no other treatment options available. Patients at increased risk include those with a history of aortic aneurysms, PAVD, hypertension, certain genetic conditions such as Marfan Syndrome or Ehlers-Danlos syndrome, and the elderly. Read More →

Read More
Brea Neri
Allied Against Opioid Abuse Publishes Pharmacy Toolkit to Aid Pharmacist Conversations with Patients and Colleagues about Prescription Opioids

Allied Against Opioid Abuse recently published a Pharmacy Toolkit that helps pharmacists engage in conversations with their patients and healthcare provider colleagues about prescription opioids. The resources are intended to help pharmacists raise awareness among their patients about the rights, risks, and responsibilities associated with prescription opioids and navigate difficult but important conversations to help prevent opioid abuse and misuse. Read More →

Read More
Brea Neri
ANNALS OF FAMILY MEDICINE: Legacy Drug-Prescribing Patterns in Primary Care

Annals of Family Medicine – the proportion of patients having a prescription medication longer than necessary was 46% for antidepressants, 14% for bisphosphonates, and 45% for proton pump inhibitors. These data demonstrate the potential of inappropriate durations of therapy to contribute to unnecessary polypharmacy, providing an opportunity for system-level intervention in primary care with enormous potential benefit for patients. Read More →

Read More
Brea Neri